11 known cases. View patent page →
Hatch-Waxman ANDA patent infringement action in the District of New Jersey. The multi-patent Xyrem complaint included US 7,668,730 and also asserted the '059, '988, '182, and '963 patents. The case was resolved short of trial and closed.
Federal Circuit appeal from the PTAB IPR decision on U.S. 8,589,182. The court affirmed, holding the FDA Advisory Committee materials were a publicly accessible printed publication and proper prior art; the decision disposed of the family patents together.
Jazz Pharmaceuticals sued Par Pharmaceutical in D.N.J. over an ANDA for sodium oxybate oral solution. The case was consolidated with Jazz v. Amneal, No. 2:13-cv-00391, with the '988 patent among the patents-in-suit.
Jazz Pharmaceuticals filed a D.N.J. ANDA action against Watson Laboratories concerning ANDA No. 204952. The case was consolidated into No. 2:13-cv-00391, with the '988 patent among the patents-in-suit.
Jazz Pharmaceuticals and Jazz Pharmaceuticals Ireland sued Wockhardt entities in D.N.J. over ANDA No. 207526. Wockhardt filed counterclaims for declaratory judgment of invalidity/non-infringement of the '988 patent and others, and later settled before the Federal Circuit decision.
This case appears on the '988 patent litigation docket, but the narrative could not independently verify the defendants, filing date, or outcome.
Amneal and Par filed a covered business method petition against Jazz Pharmaceuticals regarding the '988 patent in 2014. The PTAB did not institute the petition and denied it on procedural grounds.
Par and Amneal petitioned for inter partes review of the '988 patent. The PTAB instituted the review and issued a final written decision on July 27, 2016 holding claims 1–15 of the '988 patent unpatentable as obvious over the Advisory Committee Art, with Korfhage as to claims 2 and 10.
Amneal filed an inter partes review against Jazz Pharmaceuticals on the '988 patent. The PTAB instituted the review and issued a final written decision in 2016 holding claims of the '988 patent unpatentable, as a companion to IPR2015-00551.
Wockhardt Bio AG filed an inter partes review against Jazz Pharmaceuticals on the '988 patent. The PTAB instituted the proceeding on October 30, 2015 and joined it with IPR2015-00551, so it was governed by the '551 final written decision.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.